机构:
Merck & Co Inc, West Point, PA 19486 USAMerck & Co Inc, West Point, PA 19486 USA
Hargreaves, Richard J.
[1
]
Rabiner, Eugenii A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Imanova Ltd Burlington, London W12 0NN, England
Kings Coll London, Ctr Neurosci Imaging, London WC2R 2LS, EnglandMerck & Co Inc, West Point, PA 19486 USA
Rabiner, Eugenii A.
[2
,3
]
机构:
[1] Merck & Co Inc, West Point, PA 19486 USA
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Imanova Ltd Burlington, London W12 0NN, England
[3] Kings Coll London, Ctr Neurosci Imaging, London WC2R 2LS, England
The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs. CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy. (C) 2013 Published by Elsevier Inc. .
机构:
Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Nucl Med, Seoul 110744, South KoreaSeoul Natl Univ, Coll Med, Canc Res Inst, Dept Nucl Med, Seoul 110744, South Korea
Chung, JK
Kang, JH
论文数: 0引用数: 0
h-index: 0
机构:
Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Nucl Med, Seoul 110744, South KoreaSeoul Natl Univ, Coll Med, Canc Res Inst, Dept Nucl Med, Seoul 110744, South Korea